Cytotheryx’ revolutionary technology takes primary human hepatocytes and propagates high-quality, dependable, and accessible cells.
The critical value of primary human hepatocytes (PHH) has been understood for decades and various attempts to produce this vital resource have been made, including the development of hepatocyte-like cells such as immortalized cell lines that can be produced in a laboratory setting, or stem cell derived progenitor cells that retain some hepatocyte function. The challenge has always been that these alternatives do not maintain the full functionality of primary human hepatocytes and thus offer limited value to the field. The initial attempts to develop bio-incubators to produce PHH focused on small volumes and provided the proof that this technology could be utilized to expand cells and maintain their full functionality.
Expanding Hepatocytes up to 1000x
With our platform technology, Cytotheryx is developing a consistent, high-quality source of primary human hepatocytes to meet the unmet need for liver cells in the life science community. In turn, these liver cells can be used in preclinical drug discovery and disease-specific research and enable therapeutic applications like liver assist devices, cell therapy, and other innovative treatments for liver disease, liver failure, and rare diseases.
Medical breakthroughs require innovative resources. Cytotheryx delivers.
